1、 实际募集资金金额和资金到账时间 经中国证券监督管理委员会证监许可〔2019〕2008 号文核准， 并经上海证券交易所同意，本公司由中信证券股份有限公司作为本次 发行的保荐人和主承销商，负责本次公开发行可转换债券发行的组织 实施。本次发行的可转换公司债券向股权登记日（2019 年 12 月 18 日）收市后登记在册的公司原股东优先配售，原股东优先配售后余额 部分（含原股东放弃优先配售部分）采用网上向社会公众投资者通过 上海证券交易所交易系统发售的方式进行。本次发行可转换公司债券 4,400,000 张，每张面值为人民币 100.00 元，按面值发行，共计募 集资金人民币 44,000.00 万元，扣除保荐承销费 821.50 万元(其中， 不含税保荐承销费为人民币 775.00 万元，该部分属于发行费用；税 款为人民币 46.50 万元，该部分不属于发行费用)后实际收到的募集 资金为人民币 43,178.50 万元，已由主承销商中信证券股份有限公司 于 2019 年 12 月 25 日汇入本公司募集资金监管账户。另减除律师费、 会计师费、资信评级费、债券发行登记费和法定信息披露费等其他发 行费用(均不含税 ...

2022 可持续发展报告 暨ESG(环境、社会及治理)报告 振德医疗用品股份有限公司 目录 2022 可持续发展报告 暨 ESG（环境、社会及治理）报告 目录 | 关于本报告 | 03 | | --- | --- | | 关于振德医疗 | 04 | | 董事长致辞 | 05 | | �从 Care 到 We Care | | | 2022 年可持续发展关键绩效 | 07 | 02 可持续发展管理 | ESG 战略 | 17 | | --- | --- | | ESG 管理架构 | 19 | | 利益相关方沟通 | 19 | | 实质性议题分析 | 21 | 04 | 关爱，保障员工权益与福利 | 35 | | --- | --- | | 投入，携手员工共同成长 | 38 | | 坚守，维护员工安全与健康 | 42 | 01 责任行动 | 员工关怀 | 11 | | --- | --- | | 社区沟通 | 12 | | 社会捐赠 | 14 | 03 合规为先，勇于变革 | 规范治理，保护投资者权益 | 25 | | --- | --- | | 合规经营，恪守商业道德 | 27 | | 持续变革，谋求长久发展 ...

Financial Performance - The company's operating revenue for 2022 reached CNY 6,137,634,431.69, representing a year-on-year increase of 20.54% compared to CNY 5,091,572,447.78 in 2021[23]. - The net profit attributable to shareholders of the listed company was CNY 703,226,016.47, a significant increase of 40.09% from CNY 501,983,606.77 in the previous year[23]. - The net cash flow from operating activities increased by 52.40% to CNY 1,246,045,055.93, compared to CNY 817,629,318.83 in 2021[23]. - Total assets at the end of 2022 amounted to CNY 7,896,933,885.12, reflecting a growth of 22.97% from CNY 6,421,676,690.51 at the end of 2021[24]. - The company reported a net asset attributable to shareholders of CNY 5,541,678,060.39, which is a 36.27% increase from CNY 4,066,740,693.18 at the end of 2021[24]. - Basic earnings per share for 2022 increased by 8.71% to CNY 2.87 compared to CNY 2.64 in 2021[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 33.18% to CNY 2.97 per share in 2022 from CNY 2.23 in 2021[25]. - The gross profit margin was 35.00%, a decrease of 0.95% compared to the previous year, primarily due to the price normalization of isolation protective products[75]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of CNY 7.50 per 10 shares (including tax), totaling CNY 199,741,320 based on 266,321,760 shares[6]. - The total cash dividend amount (including tax) is CNY 312,857,887.89, which accounts for 45.93% of the net profit attributable to ordinary shareholders[182]. - The company emphasizes continuous and stable cash dividends to enhance long-term investment returns for shareholders[178]. - The cash dividend proposal is subject to approval at the 2022 annual general meeting[179]. Market and Business Expansion - The company achieved a main business revenue of 6.131 billion yuan, a year-on-year increase of 24.94%, with net profit attributable to shareholders reaching 681 million yuan, up 14.31%[37]. - Domestic main business revenue reached 4.104 billion yuan, a year-on-year increase of 90.62%, with hospital line revenue at 2.713 billion yuan, excluding isolation protective products[39]. - The company expanded its coverage to over 7,000 hospitals nationwide, an increase of nearly 1,000 hospitals compared to the beginning of the reporting period, including over 1,000 top-tier hospitals[38]. - The company’s international main business revenue was 2.027 billion yuan, a decrease of 26.40% year-on-year, primarily due to high sales of isolation protective products in the previous year[41]. - The company is focused on solidifying its management foundation and improving economic efficiency amid a complex external environment[36]. Research and Development - Research and development expenses increased by 48.23% to 227 million RMB, indicating a strong commitment to innovation[72]. - The company emphasized R&D investment, establishing a medical device industry innovation consortium to enhance technical innovation capabilities[43]. - The company has established a mechanism for intellectual property protection in the pharmaceutical procurement sector, indicating a strategic focus on compliance and innovation[104]. - The company is committed to investing in R&D, focusing on key technologies in infection control and wound care, and exploring sustainable materials for product development[129]. Acquisitions and Investments - The company acquired 100% equity of MIDMEDS LIMITED in the UK, expanding its channel coverage and enhancing its product portfolio in surgical infection control[49]. - The company completed a capital increase of 137.06 million RMB in its wholly-owned subsidiary, Shaoxing Zhend Medical Supplies Co., Ltd., maintaining 100% control[108]. - The company invested 100 million RMB in Anhui Meidis, also retaining 100% control post-capital increase[109]. - The company plans to acquire 100% equity of Jiangsu Yinbeisi Technology Development Co., Ltd. for 24.33 million Yuan, focusing on pre-filled catheter flushing products[137]. Governance and Compliance - The company’s governance practices comply with relevant laws and regulations, with no significant discrepancies noted[143]. - The company has established a comprehensive governance structure to enhance investor relations and protect minority shareholders' rights[197]. - The company has implemented measures to ensure the independence of its assets, personnel, and operations[143]. - The company’s financial resolutions and proposals for related party transactions were also approved during the annual meeting[146]. Employee and Organizational Development - The total number of employees in the parent company is 1,524, while the total number of employees in major subsidiaries is 6,961, resulting in a combined total of 8,485 employees[172]. - The company has established a competitive compensation policy that includes basic salary, performance assessment, and bonus incentives, focusing on employee performance and contributions[174]. - The company has implemented a comprehensive training program to enhance employee skills and organizational capabilities[175]. Environmental and Social Responsibility - The company has implemented internal environmental management systems, including water pollution prevention and solid waste management[194]. - The company emphasizes energy conservation and pollution reduction as part of its sustainable development strategy[197]. - The company actively participates in social responsibility initiatives, including donations of medical supplies[197].

Financial Performance - The company's operating revenue for Q1 2023 was CNY 1,300,476,798.62, representing a year-on-year increase of 2.82%[5] - Net profit attributable to shareholders was CNY 146,461,478.20, reflecting a significant increase of 30.92% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 140,905,813.96, up by 40.80% year-on-year[5] - Basic earnings per share were CNY 0.55, an increase of 10.00% year-on-year, while diluted earnings per share also rose by 12.24% to CNY 0.55[5] - Total operating revenue for Q1 2023 was ¥1,300,476,798.62, an increase of 2.1% compared to ¥1,264,804,817.53 in Q1 2022[18] - Net profit for Q1 2023 reached ¥147,985,140.95, a 26.4% increase from ¥117,009,646.57 in Q1 2022[20] - Earnings per share for Q1 2023 were ¥0.55, compared to ¥0.50 in Q1 2022, indicating a growth of 10%[20] - The company reported a total comprehensive income of ¥169,129,872.78 for Q1 2023, compared to ¥117,009,646.57 in Q1 2022, indicating a significant increase[20] Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -205,371,184.05, a decrease of 273.44% compared to the previous year[5] - In Q1 2023, the company's cash inflow from operating activities was CNY 1,397,604,503.80, a decrease of 3.93% compared to CNY 1,454,945,120.54 in Q1 2022[22] - The net cash flow from operating activities was negative at CNY -205,371,184.05, contrasting with a positive CNY 118,412,693.12 in the same period last year[22] - Total cash outflow from operating activities increased to CNY 1,602,975,687.85, up from CNY 1,336,532,427.42 in Q1 2022, marking a rise of 19.9%[22] - The company reported a net cash flow from investing activities of CNY -387,477,924.05, worsening from CNY -232,350,285.63 in Q1 2022[23] - Cash inflow from financing activities was CNY 534,900,000.00, an increase of 37.5% compared to CNY 389,000,000.00 in Q1 2022[23] - The net cash flow from financing activities improved to CNY 474,244,778.31, compared to CNY 131,754,828.90 in the previous year[23] - The ending balance of cash and cash equivalents was CNY 1,933,679,374.82, up from CNY 1,331,217,048.92 in Q1 2022[23] - The company experienced a negative impact of CNY -8,335,479.50 from foreign exchange fluctuations on cash and cash equivalents[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 8,119,014,236.49, up 2.81% from the end of the previous year[6] - The total liabilities as of Q1 2023 were ¥2,187,697,538.68, slightly up from ¥2,139,939,039.32 in Q1 2022[16] - The total current liabilities increased to RMB 1,292,000,000.00 from RMB 1,200,000,000.00, reflecting a rise of approximately 7.7%[15] - The company's cash and cash equivalents decreased to RMB 1,948,595,711.94 from RMB 2,075,107,919.75, representing a decline of about 6.1%[14] - The company's inventory remained stable at RMB 931,538,922.77, slightly up from RMB 929,587,857.11, indicating a marginal increase[15] - The company's goodwill increased to RMB 577,208,353.10 from RMB 474,485,730.66, showing an increase of about 21.7%[15] - The total equity attributable to shareholders increased to ¥5,716,303,658.29 in Q1 2023, compared to ¥5,541,678,060.39 in Q1 2022, reflecting a growth of 3.2%[16] Business Operations - The company reported a decrease of 22.72% in the main business income from isolation protective products, while excluding this, the main business income increased by 21.54%[8] - Research and development expenses increased to ¥42,093,960.50 in Q1 2023, up from ¥32,913,801.70 in Q1 2022, marking a rise of 27.7%[18] - The company completed the acquisition of 100% equity in Jiangsu Yinbeisi Technology Development Co., Ltd. for RMB 24,330,000, focusing on pre-filled catheter flushing products[13] - The company’s subsidiary, Rocialle Healthcare, acquired 100% of Dene Healthcare Limited for GBP 1,737.16 million, with the transaction completed in January 2023[13] - The company established FULLCARE (KENYA) MEDICAL SEZ LIMITED with a registered capital of 120,000 million Kenyan Shillings, focusing on wound care and surgical infection control products[12] - The company's trading financial assets increased to RMB 255,757,608.95, up from RMB 99,667,468.12, marking a significant increase of approximately 156.5%[14] - The total cash outflow for investing activities was CNY 387,640,364.33, significantly higher than CNY 239,982,604.95 in Q1 2022[23]

证券代码：603301 证券简称：振德医疗 公告编号：2023-015 振德医疗用品股份有限公司关于 召开 2022 年度暨 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、会议召开时间：2023 年 5 月 9 日（星期二）10:00-11:00 2、会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 3、会议召开方式：上证路演中心网络互动 4、投资者可于 2023 年 4 月 27 日（星期四） 至 5 月 8 日（星 期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目 或通过本公告后附的电话、传真和指定邮箱进行提问。公司将在说明 会上选择投资者普遍关注的问题进行回答。 振德医疗用品股份有限公司（以下简称"公司"）已于 2023 年 4 月 26 日发布公司 2022 年度报告以及 2023 年第一季度报告。为便于 广大投资者更全面深入地了解公司2022 年度和2023 年一季度经营成 果、财 ...

Financial Performance - The company's operating revenue for Q3 2022 reached ¥1,430,511,294.36, representing a year-on-year increase of 50.49%[7] - Net profit attributable to shareholders was ¥183,469,306.96, up 75.86% compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥170,655,082.65, reflecting a significant increase of 109.26% year-on-year[7] - Basic earnings per share for the quarter were ¥0.81, an increase of 76.09% from the previous year[10] - Total operating revenue for the first three quarters of 2022 reached CNY 4,197,542,725.56, an increase from CNY 3,862,648,045.72 in the same period of 2021, representing a growth of approximately 8.7%[31] - The net profit for the current period is CNY 462,971,053.32, a decrease of 21% compared to CNY 585,594,652.61 in the previous period[36] - The total profit for the current period is CNY 511,616,644.69, down from CNY 668,071,178.86, reflecting a decline of approximately 23%[36] - The operating profit stands at CNY 517,283,539.26, compared to CNY 668,686,550.96 in the previous period, indicating a decrease of about 23%[36] - The total comprehensive income attributable to the parent company's shareholders is CNY 455,043,460.39, down from CNY 482,529,812.69, reflecting a decrease of about 5.7%[38] - The basic earnings per share for the current period is CNY 2.02, a slight decrease from CNY 2.12 in the previous period[38] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥7,436,622,969.47, marking a 15.81% increase from the end of the previous year[10] - The company's total assets increased to CNY 7,436,622,969.47 from CNY 6,421,676,690.51, marking a growth of about 15.8%[33] - Total liabilities decreased to CNY 1,877,872,137.63 from CNY 1,982,076,740.76, showing a reduction of approximately 5.3%[33] - Accounts receivable reached RMB 827,060,024.40, up from RMB 690,396,879.50 in the previous year[25] Cash Flow - The company reported a net cash flow from operating activities of ¥301,735,384.37 for the year-to-date, which is a decrease of 41.35% year-on-year[10] - The cash flow from operating activities is CNY 301,735,384.37, down from CNY 514,487,076.18, representing a decline of approximately 41%[41] - The cash inflow from operating activities totaled CNY 4,888,908,254.18, an increase from CNY 4,534,671,652.40 in the previous period[41] - The cash flow from investing activities shows a net outflow of CNY 623,768,264.99, compared to a smaller outflow of CNY 37,444,008.64 in the previous period[42] - The cash flow from financing activities resulted in a net inflow of CNY 623,897,439.24, contrasting with a net outflow of CNY 282,031,429.03 in the previous period[42] Shareholder Information - The total number of common shareholders at the end of the reporting period is 22,675, with the largest shareholder, Zhejiang Zhend Medical Holdings Co., Ltd., holding 49.82% of shares[18] - The company completed a private placement of 39,246,466 shares, increasing its registered capital to RMB 266,451,202[24] - The top ten shareholders hold a combined 62.52% of the company's shares, indicating a concentrated ownership structure[18] - The company has no pledged, marked, or frozen shares among its major shareholders[18] - The largest shareholder, Zhejiang Zhend Medical Holdings Co., Ltd., also holds shares in Xuchang Zhend Landscape Engineering Co., Ltd., indicating a potential related party relationship[21] Market Strategy and Future Plans - The company plans to continue expanding its market presence and enhancing brand influence to sustain revenue growth[11] - The company plans to repurchase shares with a total amount between RMB 75 million and RMB 150 million, with a maximum price of RMB 60 per share[24] - The company has repurchased a total of 290,549 shares, representing 0.1090% of the total share capital, with a transaction amount of RMB 13,394,681.62[24] - The company has indicated a focus on strategic acquisitions to enhance its competitive position in the market[31] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[31] Research and Development - Research and development expenses amounted to CNY 160,613,197.60, compared to CNY 105,536,290.91 in the previous year, reflecting a rise of approximately 52.2%[31] Non-Recurring Gains and Losses - Non-recurring gains and losses for the quarter included government subsidies of ¥69,399,111.50, contributing to the overall profit increase[11] - The company experienced a decrease in other comprehensive income, with a net amount of CNY -41,713,592.91 compared to CNY 1,089,635.19 in the previous period[36] Revenue from Specific Products - The revenue from epidemic prevention protective products increased by 98% year-on-year, although it decreased by 27% compared to Q2 2022[11]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥2,767,031,431.20, a decrease of 4.98% compared to ¥2,912,105,568.85 in the same period last year[22]. - The net profit attributable to shareholders for the first half of 2022 was ¥271,574,153.43, down 28.19% from ¥378,203,869.98 in the previous year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥283,036,443.39, a decrease of 16.41% compared to ¥338,605,771.21 in the same period last year[22]. - The net cash flow from operating activities was ¥85,271,465.41, a significant decline of 74.84% from ¥338,953,666.48 in the previous year[22]. - Basic earnings per share for the first half of 2022 were ¥1.21, down 27.11% from ¥1.66 in the same period last year[25]. - The diluted earnings per share were ¥1.20, a decrease of 27.71% compared to ¥1.66 in the previous year[25]. - The weighted average return on net assets was 6.52%, a decrease of 2.31 percentage points from 8.83% in the previous year[25]. - The company's revenue for Q2 2022 was 1.502 billion RMB, an increase of 18.77% compared to Q1 2022[26]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, for Q2 2022 was 183 million RMB, up 82.82% from Q1 2022[26]. - The net profit attributable to the parent company for Q2 2022 was 160 million RMB, an increase of 42.75% compared to Q1 2022[26]. Assets and Liabilities - The total assets at the end of the reporting period were ¥7,125,746,328.34, an increase of 10.96% from ¥6,421,676,690.51 at the end of the previous year[22]. - The net assets attributable to shareholders at the end of the reporting period were ¥4,198,276,902.97, up 3.23% from ¥4,066,740,693.18 at the end of the previous year[22]. - Total liabilities reached RMB 2,732,328,057.94, compared to RMB 1,982,076,740.76, indicating a rise of 37.8%[177]. - Short-term borrowings increased to RMB 904,879,124.47, compared to RMB 660,725,916.67, a growth of 36.8%[175]. - Long-term borrowings rose to RMB 525,505,138.89, compared to RMB 145,155,069.44, representing an increase of 262.5%[175]. Market Position and Strategy - The company has established a marketing network covering over 6,300 hospitals across China, including more than 950 top-tier hospitals[31]. - The company ranks among the top three in China's medical dressing exports for several consecutive years[31]. - The company focuses on medical-grade personal care and family health care products, with a wide range of offerings[31]. - The company has developed efficient business cooperation systems with many well-known foreign medical device brands[31]. - The company’s products are recognized in over 70 countries and regions worldwide, including Europe, North America, and Asia[31]. - The company achieved a nationwide coverage rate of 97% in top 100 chain pharmacies, reaching over 100,000 pharmacy stores and more than 15,000 supermarkets and convenience stores[34]. - The company operates over 10 online stores on platforms like Tmall, JD.com, and Pinduoduo, with a total fan base exceeding 6 million[34]. - The company is focused on expanding its market presence both online and offline, leveraging its brand influence[34]. Research and Development - Research and development expenses increased by 32.99% to ¥98,734,445.53, reflecting the company's commitment to innovation and product development[76]. - The company is focusing on R&D investments, enhancing material analysis capabilities, and developing new products to meet clinical needs, including antimicrobial dressings[69]. - The company has established an independent marketing team for modern wound care products and set up a marketing team overseas to enhance market share[67]. Risks and Challenges - The company faces risks from regulatory changes in the healthcare sector, which could impact operations if not adapted to new policies[5]. - Product quality risks are significant due to the nature of medical supplies, necessitating strict quality control measures to maintain safety and reliability[5]. - Market risks include increased competition in both domestic and international markets, particularly from lower-cost regions[5]. - The company is enhancing its supply chain and quality management systems to mitigate risks associated with product quality and market competition[5]. Corporate Governance and Commitments - The company elected new board members including Wang Jiafen, Ni Ya, Li Shengxiao, and Zhu Chafen as independent directors[101]. - The company did not distribute profits or increase capital reserves, with no dividends or stock bonuses declared[105]. - The company has committed to a gradual reduction plan post-lock-up, limiting annual sales to no more than 5% of the total shares outstanding at the end of the previous year[121]. - The company will ensure that any profits gained from non-compliance with commitments will be returned to the company within five working days[124]. - The company has established measures to extend the lock-up period by three months if any commitments are violated[121]. Environmental and Social Responsibility - The company has not faced any environmental penalties and emphasizes green development and compliance with environmental regulations[112]. - The company has established an ISO system for environmental management and promotes energy-saving and emission-reduction initiatives[115]. - The company has implemented measures to enhance employee environmental awareness and increase investment in environmental protection[115].

Financial Performance - The company's operating revenue for 2021 was ¥5,091,572,447.78, a decrease of 51.04% compared to ¥10,398,545,638.73 in 2020[23]. - Net profit attributable to shareholders was ¥595,861,926.07, down 76.63% from ¥2,549,453,200.21 in the previous year[23]. - The net cash flow from operating activities decreased by 73.80% to ¥817,629,318.83 from ¥3,120,839,894.43 in 2020[23]. - Basic earnings per share fell to ¥2.64, a decline of 78.88% compared to ¥12.50 in 2020[23]. - The weighted average return on equity decreased to 14.22%, down 80.66 percentage points from 94.88% in 2020[23]. - The decline in revenue was primarily due to a decrease in sales of pandemic-related protective products as the domestic pandemic was effectively controlled[24]. - The gross profit margin was negatively impacted by global freight capacity shortages, exchange rate fluctuations, and rising raw material prices[26]. - The company achieved a total revenue of 4.907 billion RMB, a decrease of 52.41% year-on-year, but an increase of 164.43% compared to 2019[35]. - Revenue from epidemic prevention products reached 1.669 billion RMB, while excluding these products, the revenue was 3.238 billion RMB, reflecting a year-on-year growth of 17.87%[35]. - The net profit attributable to the parent company was 596 million RMB, down 76.63% year-on-year, but up 279.80% compared to 2019[35]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 6.00 CNY per 10 shares, totaling 136,322,841.60 CNY (including tax) for the 2021 fiscal year[6]. - The company’s total unallocated profits will be carried forward to the next fiscal year after the dividend distribution[6]. - The company has committed to a three-year shareholder return plan for 2021-2023, emphasizing its focus on shareholder value[177]. - The total number of shares held by directors and senior management decreased from 10,864,525 at the beginning of the year to 10,567,525 at the end of the year, a reduction of 297,000 shares[180]. - The total pre-tax remuneration for directors and senior management during the reporting period amounted to 1,069.82 million yuan[180]. Corporate Governance and Compliance - The company reported a standard unqualified audit opinion from Tianjian Accounting Firm for the fiscal year 2021[5]. - The company’s board of directors and supervisory board members have confirmed the accuracy and completeness of the annual report[4]. - The company has established a comprehensive internal control system to enhance corporate governance and risk management capabilities[172]. - The company strictly adheres to information disclosure regulations, ensuring timely and accurate communication with all shareholders[172]. - The audit committee, nomination committee, and compensation committee are all chaired by independent directors, ensuring a majority of independent oversight[173]. Risk Management - The company has detailed potential risks in the report, which can be found in the section discussing future development[8]. - The company’s future plans and strategic developments are subject to investment risks, as stated in the forward-looking statements[7]. - The company faces risks related to regulatory changes in the healthcare industry, which could impact its operations if it fails to adapt to new policies[162]. - The company is experiencing increased competition in the medical dressing export market due to geopolitical uncertainties and rising domestic labor costs[165]. - The company is actively managing risks associated with fluctuations in exchange rates, raw material prices, and shipping costs through strategic pricing mechanisms and forward contracts[165]. Research and Development - The company invested in various information technology systems to enhance operational efficiency and support business development[43]. - The company is committed to increasing its research and development investment, focusing on surgical infection control materials and ostomy wound care technologies[153]. - The company has established a quality management system certified by ISO13485 and has passed multiple inspections by the FDA and local drug regulatory authorities, ensuring product quality[74]. - The company holds 51 invention patents and 486 utility model patents, along with 93 Class II and 9 Class III medical device registrations, enhancing its innovation capabilities[74]. - The company is focused on continuous innovation in product design and technology to meet the evolving needs of the healthcare market[64]. Market Expansion and Strategy - The company aims to become a leading healthcare enterprise with a target of reaching a market value of 100 billion RMB through a multi-channel marketing strategy focused on "medical + health"[146]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of the next fiscal year[186]. - The company plans to enhance its digital marketing efforts, aiming for a 50% increase in online sales[186]. - The company is actively pursuing market expansion through acquisitions, as evidenced by the acquisition of Anhui Lanxin and Shanghai Yao, which has broadened its product portfolio[122]. - The company plans to strengthen its regulatory compliance and monitoring mechanisms to ensure product quality and safety throughout the product lifecycle[122]. Operational Efficiency - The company implemented significant organizational and talent development initiatives to support rapid growth and improve operational efficiency[41]. - The company achieved a gross margin improved to 45%, up from 40% in the previous year, indicating better cost management[186]. - The company aims to improve production efficiency and product quality through lean management practices and automation upgrades[158]. - The company has emphasized lean manufacturing and has optimized its production processes, leading to improved supply chain efficiency and cost reduction[74]. - The company plans to enhance its digital infrastructure, including the completion of the second phase of its CRM system to improve operational management capabilities[154]. Acquisitions and Investments - The company acquired 100% equity of Shanghai Yaoao and Nantong Zhend, and increased its stake in Anhui Lanxin to 60% during the reporting period[96]. - The company approved an investment of approximately CNY 650 million for the construction of a new medical device production base and research institute in Shaoxing, Zhejiang Province, with land acquisition costs of CNY 45.13 million for 66,852 square meters[137]. - The company is in the process of expanding its surgical infection control production line with a total investment of CNY 845 million, which is currently under construction[137]. - The company is exploring potential acquisitions to enhance its product portfolio and market reach[186]. - The company has proposed a non-public issuance of A-shares for 2021, with a feasibility analysis report on the use of raised funds[198].

Financial Performance - Revenue for Q3 2021 was CNY 950,542,476.87, a decrease of 77.88% compared to the same period last year[7] - Net profit attributable to shareholders for Q3 2021 was CNY 104,325,942.71, down 90.59% year-on-year[7] - Basic earnings per share for Q3 2021 was CNY 0.46, a decline of 91.40% compared to the previous year[9] - Revenue for the year-to-date period was CNY 3,862,648,045.72, down 52.41% year-on-year[7] - Net profit attributable to shareholders for the year-to-date period was CNY 482,529,812.69, a decrease of 77.00% compared to the previous year[7] - Total operating revenue for the first three quarters of 2021 was CNY 3,862,648,045.72, a decrease from CNY 8,116,660,488.11 in the same period of 2020, representing a decline of approximately 52.3%[26] - Net profit for the first three quarters of 2021 was CNY 585,594,652.61, compared to CNY 2,409,971,170.87 in 2020, reflecting a decrease of approximately 75.7%[33] - The total comprehensive income attributable to the parent company for the first three quarters of 2021 is CNY 482,529,812.69, compared to CNY 2,097,753,320.69 in the same period of 2020, indicating a significant decrease[35] Assets and Liabilities - Total assets as of the end of Q3 2021 were CNY 6,782,938,953.56, an increase of 5.98% from the end of the previous year[9] - The company's total assets as of September 30, 2021, are approximately ¥6.78 billion, compared to ¥6.40 billion at the end of 2020[24] - The company's total liabilities amounted to CNY 2,465,310,794.24, an increase from CNY 1,933,193,883.17 in the previous year, showing a growth of about 27.5%[26] - The total liabilities increased to approximately ¥2.10 billion from ¥1.74 billion year-over-year[24] - Current liabilities reached approximately $1.74 billion, remaining unchanged from the previous period[47] - Total liabilities were approximately $1.93 billion, down by $62.66 million compared to the previous period[47] Cash Flow - Cash flow from operating activities for the year-to-date period decreased by 80.76% to CNY 514,487,076.18[9] - Net cash flow from operating activities for the first three quarters of 2021 is CNY 514,487,076.18, a decrease from CNY 2,673,731,914.25 in the same period of 2020[39] - Cash inflow from operating activities totaled CNY 4,534,671,652.40 in the first three quarters of 2021, compared to CNY 8,968,332,752.97 in the same period of 2020[39] - The company reported a net increase in cash and cash equivalents of CNY 190,195,182.89 for the first three quarters of 2021, compared to an increase of CNY 1,321,802,813.74 in the same period of 2020[39] Shareholder Information - The total number of common shareholders at the end of the reporting period is 46,055[15] - Zhejiang Zhend Medical Holdings Co., Ltd. holds 48.06% of the shares, making it the largest shareholder[15] - The top ten shareholders collectively hold 83.50% of the shares, indicating a high level of concentration[17] - The company has no preferred shareholders with restored voting rights[15] Operational Costs and Expenses - Total operating costs for the first three quarters of 2021 were CNY 3,257,979,534.49, down from CNY 5,206,925,389.74 in 2020, indicating a reduction of about 37.4%[29] - Research and development expenses for the first three quarters of 2021 were CNY 105,536,290.91, compared to CNY 166,626,599.77 in 2020, a reduction of about 36.6%[29] - The company reported a profit from operations of CNY 668,686,550.96, significantly lower than CNY 2,899,823,827.82 in the same period of 2020, a decline of approximately 77.0%[31] - The company’s financial expenses decreased to CNY 5,716,071.15 from CNY 48,082,599.43, a reduction of approximately 88.1%[29] Market Conditions - The decline in revenue and profit was attributed to the normalization of prices for pandemic-related protective products and increased shipping costs due to global supply chain issues[11] Other Financial Metrics - The weighted average return on equity decreased by 34.76 percentage points to 2.63% in Q3 2021[9] - The company's cash and cash equivalents as of September 30, 2021, amount to approximately ¥1.95 billion, an increase from ¥1.81 billion at the end of 2020[21] - Total current assets decreased to approximately ¥3.73 billion from ¥4.35 billion year-over-year[21] - Short-term borrowings increased to approximately ¥646.84 million from ¥358.37 million year-over-year[24] - The company reported a decrease in inventory to approximately ¥821.55 million from ¥1.08 billion year-over-year[21] - The company’s deferred income tax liabilities increased to CNY 37,619,757.21 from CNY 7,855,497.98, indicating a growth of about 377.5%[26] - The company adopted new leasing standards effective January 1, 2021, impacting the accounting treatment of lease liabilities and right-of-use assets[48]

Financial Performance - The company's operating revenue for the first half of 2021 was ¥2,912,105,568.85, a decrease of 23.76% compared to ¥3,819,840,910.57 in the same period last year[25]. - The net profit attributable to shareholders of the listed company was ¥378,203,869.98, down 61.74% from ¥988,568,649.97 in the previous year[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥338,605,771.21, a decrease of 65.60% compared to ¥984,201,245.76 in the same period last year[25]. - The net cash flow from operating activities was ¥338,953,666.48, down 85.11% from ¥2,276,369,995.53 in the previous year[25]. - Basic earnings per share decreased to CNY 1.66, down 67.06% compared to the same period last year[26]. - Diluted earnings per share also fell to CNY 1.66, a decrease of 62.70% year-over-year[26]. - The weighted average return on equity dropped to 8.83%, a decrease of 44.52 percentage points compared to the previous year[26]. - The company achieved a total revenue of 2,907.10 million yuan in the first half of 2021, a decrease of 23.79% compared to the same period last year, but an increase of 284.72% compared to the first half of 2019[50]. - The net profit attributable to the parent company was 378.20 million yuan, down 61.74% year-on-year, but up 529.24% compared to the first half of 2019[50]. Assets and Liabilities - Total assets at the end of the reporting period were ¥6,492,339,601.75, an increase of 1.44% compared to ¥6,400,086,700.05 at the end of the previous year[25]. - The net assets attributable to shareholders of the listed company at the end of the reporting period were ¥3,905,266,172.22, a decrease of 6.63% from ¥4,182,785,620.66 at the end of the previous year[25]. - The company's total equity was CNY 4,264,976,257.12, down from CNY 4,466,892,816.88, a decrease of 4.52%[172]. - Total liabilities amounted to CNY 2,227,363,344.63, an increase of 15.23% compared to CNY 1,933,193,883.17 from the previous period[172]. - The company's cash and cash equivalents increased by 25.95% to CNY 2,278,426,000, representing 35.09% of total assets[65]. Sales and Market Strategy - The company has established a marketing network covering over 5,600 hospitals across China, including nearly 900 top-tier hospitals[34]. - The company has over 10 online stores on major e-commerce platforms, with a total fan base exceeding 5 million[34]. - The company focuses on expanding its product lines in both medical and health sectors, including personal care and family health products[34]. - The company is expanding its professional sales and channel teams in the domestic hospital market, aiming to improve sales efficiency and market penetration by over 20%[50]. - The company has achieved a 43.16% year-on-year increase in domestic hospital line sales, reaching 307.74 million yuan, compared to a growth of 81.21% from the first half of 2019[53]. Research and Development - The company is investing in research and development for innovative healthcare solutions, including advanced wound dressings and antiseptic products[39]. - The company has established a comprehensive quality management system certified by ISO13485, enhancing its market competitiveness[46]. - The company launched 4 invention patents and 63 utility model patents during the reporting period, enhancing its technological and competitive edge[56]. - The company reported R&D expenses of CNY 74,240,498.22, slightly up from CNY 73,200,102.13 in the first half of 2020[184]. Risks and Challenges - The company has detailed potential risks in the report, which can be found in the "Management Discussion and Analysis" section[8]. - The company faces risks related to regulatory changes in the medical device industry, which could impact operations if not adapted to timely[81]. - Product quality risks are significant due to the nature of the medical products, and the company is enhancing its quality management systems to mitigate these risks[81]. - The company is exposed to market risks, including increased competition and fluctuating demand for medical products, particularly in the context of global health crises[81]. Strategic Initiatives - The company plans to enhance its market presence through strategic partnerships and potential acquisitions in the healthcare sector[39]. - The company approved a share repurchase plan with a total fund of no less than RMB 120 million and no more than RMB 160 million, with a maximum repurchase price of RMB 90 per share[84]. - The company plans to acquire 30% of Suzhou Medis Medical Sports Goods Co., Ltd. for a total transaction amount of RMB 87 million, which will make Medis a wholly-owned subsidiary[84]. - The company aims to enhance its brand image through a new logo and digital marketing strategies, focusing on consumer interaction and brand loyalty[56]. Environmental and Compliance Commitments - The company emphasized its commitment to environmental protection and green development during its operations[100]. - The company committed to strict adherence to pre-IPO promises, including timely disclosure of any failures to fulfill commitments and compensation for investor losses[111]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[100].